Statistics and Quantitative Sciences, Data and Quantitative Sciences Institute, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
Auto-generated profile, based on publicly available information
Kaili Ren
Statistics and Quantitative Sciences, Data and Quantitative Sciences Institute, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
This retrospective cohort study compared patient characteristics and burden of infection in patients with mature B cell malignancies with and without secondary immunodeficiency disease (SID). Data were extracted from the Humedica database (H-DB) and Guardian Research Network (GRN) database from October 1, 2015 to March 10, 2020, including a 6-month pre-index period (PIP) and 12-month follow-up. Patients aged ≥18 years diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma, multiple myeloma, or non-Hodgkin's lymphoma in the PIP were stratified into 2 cohorts: SID (hypogammaglobulinemia [using ICD-10-CM codes] or serum IgG levels <5.0 g/L, both with signs and symptoms of SID or at least 1 infection) and no-SID. Patients with SID or primary immunodeficiency diseases in the PIP were excluded. Overall, 2221 patients with SID (H-DB/GRN: n = 1959/262), and 19,141 patients without SID (n = 17,598/1543) were included. Baseline characteristics were similar across cohorts. At 12-month follow-up, significantly more patients with SID had experienced ≥1 infection and ≥1 severe bacterial infection than those without SID (both P < .001). H-DB/GRN mean (standard deviation) number of severe bacterial infections was 7.6 (9.9)/2.9 (2.7) for the SID cohort versus 5.2 (6.8)/2.4 (2.2) for the no-SID cohort. This study confirms that patients with mature B cell malignancies and SID face a significantly higher burden of infections than those without SID.
Patients with multiple myeloma (MM) and secondary immunodeficiency (SID) are at risk of infection‐related morbidity and mortality owing to the disease process and treatment toxicity. This retrospective cohort study used anonymized data from the Optum‐Humedica database (October 2015–March 2020) to assess the burden of infection in patients with MM and SID versus patients without SID. Patients aged ≥ 18 years with confirmed MM were assigned to SID and no‐SID cohorts using an algorithm considering serum IgG levels < 5.0 g/L, hypogammaglobulinemia diagnosis codes, and ≥ 1 major infection. Patients with SID were stratified into those treated or not treated with immunoglobulin replacement therapy (IgRT and no‐IgRT cohorts). At 12 months follow‐up, a greater proportion of the SID cohort than the no‐SID cohort experienced infections (58.9% vs. 31.3%; p < 0.001), severe infections (29.8% vs. 10.6%, p < 0.001), and infection‐related hospitalizations (26.9% vs. 9.1%; p < 0.001). Bacterial infections were the most common infection type (SID cohort, 49.2%; no‐SID cohort, 26.1%; IgRT cohort, 70.4%; no‐IgRT cohort, 45.1%). Use of anti‐infectives and healthcare resource utilization was higher in the SID cohort than in the no‐SID cohort. Median overall survival was shorter in the SID versus no‐SID cohort (12.6 vs. 14.7 months; p < 0.001) and was similar in the IgRT versus no‐IgRT cohort (8.5 vs. 12.5 months; p = 0.446). Among patients with MM and SID, the higher infection burden in patients treated with IgRT than no‐IgRT suggests the IgRT cohort was a more vulnerable population. A better understanding of SID burden may improve outcomes for patients with MM.